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Mammalian natriuretic peptides (NPs) have been extensively investigated for use as
therapeutic agents in the treatment of cardiovascular diseases. Here, we describe the
isolation, sequencing and tridimensional homology modeling of the ﬁrst C-type natriuretic
peptide isolated from scorpion venom. In addition, its effects on the renal function of rats
and on the mRNA expression of natriuretic peptide receptors in the kidneys are delineated.
Fractionation of Tityus serrulatus venom using chromatographic techniques yielded a
peptide with a molecular mass of 2190.64 Da, which exhibited the pattern of disulﬁde
bridges that is characteristic of a C-type NP (TsNP, T. serrulatus Natriuretic Peptide). In the
isolated perfused rat kidney assay, treatment with two concentrations of TsNP (0.03 and
0.1 mg/mL) increased the perfusion pressure, glomerular ﬁltration rate and urinary ﬂow.
After 60 min of treatment at both concentrations, the percentages of sodium, potassium
and chloride transport were decreased, and the urinary cGMP concentration was elevated.
Natriuretic peptide receptor-A (NPR-A) mRNA expression was down regulated in the
kidneys treated with both concentrations of TsNP, whereas NPR-B, NPR-C and CG-C mRNAs
were up regulated at the 0.1 mg/mL concentration. In conclusion, this work describes the
isolation and modeling of the ﬁrst natriuretic peptide isolated from scorpion venom. In
addition, examinations of the renal actions of TsNP indicate that its effects may be related
to the activation of NPR-B, NPR-C and GC-C.
 2013 Elsevier Ltd. All rights reserved.fax: þ55 85 3366 8333.
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supernatant was ﬁltered with a 0.22 mm PVDF ﬁlter mem-The mammalian natriuretic peptide (NP) family consists
of atrial natriuretic peptide (ANP), brain natriuretic peptide
(B-type; BNP) and C-type natriuretic peptide (CNP), which
bind to three receptors, natriuretic peptide receptors-A
(NPR-A), -B (NPR-B) and -C (NPR-C). Both ANP and BNP
are abundantly expressed in the heart and are secreted
mainly from the atria and ventricles, respectively. However,
CNP is mainly expressed in the central nervous system,
bone and vasculature (Nishikime et al., 2010; Tobias, 2011).
Classically, the clearance of all NPs is carried out by NPR-C
and by the neutral endopeptidase (NEP); both of these
proteins are widely expressed in the kidneys, lungs and
vascular walls (Chen and Burnett, 2006).
The three mammalian NPs have been extensively
investigated for use as therapeutic agents in the treatment
of cardiovascular diseases. Over almost 30 years of
research, NPs have been found in mammals, amphibians,
reptiles, ﬁsh, and in plants. Recently, they have also been
found in bacteria (Vink et al., 2010).
The ﬁrst natriuretic peptide isolated from animal
venoms was a vasorelaxant peptide. This 38 amino acid
residue peptide was isolated from green mamba venom
and named dendroaspis natriuretic peptide (DNP). Many
natriuretic peptides have subsequently been isolated from
snake venoms, including Brazilian snakes, such as Crotalus
durissus cascavella (Evangelista et al., 2008), Bothrops jar-
araca (Higuchi et al., 1999), Bothrops moojeni (Menin et al.,
2008) and Lachesis muta (Soares et al., 2005). Many genes
encoding C-type natriuretic peptides have also been
described (Harvey, 2006).
Scorpion venoms are rich sources of small peptide
toxins. However, no natriuretic peptides have been isolated
from scorpion venom thus far. However, a new family of
peptides, called hypotensins, has been isolated from the
venom of the yellow scorpion, Tityus serrulatus. These
toxins share a similar amino acid signature with the
bradykinin-potentiating peptides (BPPs) found in snake
venoms (Verano-Braga et al., 2008, 2010). In snakes, BPPs
and CNP are encoded by the same gene (Assakura et al.,
2000).
This work describes the isolation, sequencing and
tridimensional homology modeling of the ﬁrst C-type
natriuretic peptide from scorpion venom. Its effects on the
renal function of rats and the mRNA expression of the
natriuretic peptide receptors in the kidneys were also
evaluated.
2. Materials and methods
2.1. Materials and venom
T. serrulatus venom was acquired from the Instituto
Butantan (São Paulo, Brazil). All salts and reagents were of
analytical grade andwere obtained from certiﬁed suppliers.
2.2. Isolation of the natriuretic peptide
Crude T. serrulatus venom (35 mg) was dissolved in
1.0 mL of ammonium bicarbonate buffer (1 M, pH 8.0). Thebrane. Then, 300 mL of the venom solutionwas loaded onto
a Superdex Gel Filtration Column Peptide HR10/300 GL
coupled in a semi preparative Jasco HPLC system (Easton,
MD, USA). This column was equilibrated with ammonium
bicarbonate buffer (0.25 M, pH 7.8) for 40 min before
sample application. The run conditions were adjusted to
achieve an elution rate of 0.2 mL/min. The chromatography
was simultaneously monitored at 280 and 214 nm, because
the natriuretic peptides have a higher absorption at
214 nm. The molecular masses of each fraction were
conﬁrmed by Tricine SDS-PAGE using a 16% acrylamide gel
(data not shown). Fractions with lower molecular masses
were lyophilized and stored at 4 C.
The lyophilized fractions were dissolved in TFA 0.1%
buffer (buffer A) at a ﬁnal concentration of 1 mg/mL and
centrifuged for 3 min at 4500  g. The resulting superna-
tant was applied onto an analytical reverse phase C18 col-
umn. The column had previously been equilibrated with
buffer A for 15 min before injection of the samples. Elution
was accomplished with a linear gradient of buffer B
(acetonitrile 66% in buffer A). The purity of the natriuretic
peptide fractions was assessed by Tricine SDS-PAGE. The
fractions were lyophilized and stored at 4 C.
2.3. N-terminal amino acid sequencing
Protein sequencing was performed as previously
described by Toyama et al. (2003). In brief, 2.0mgof puriﬁed
natriuretic peptide were dissolved in 200 mL of a 6 M gua-
nidine chloride solution (Merck, Germany) containing 0.4M
of Tris–HCl and 2 mM EDTA (pH 8.15). The surface of the
protein solution was next ﬂushed with nitrogen gas for
15min. After this, the reducing agent DTT (6M, 200mL)was
added to the protein solution, and the solution was then
incubated under nitrogen for 90 min. Next, 80 mL of iodo-
acetic acid was added to the solution (50 mM of cold iodo-
acetic and carboxymethylated 14C-iodoacetic acid), followed
by a third incubation under nitrogen, after which the reac-
tion tubewas sealed. A preparative C5 reverse phase column
was used to remove excess reagent and purify the peptides.
The peptides were separated by a linear gradient of aceto-
nitrile (66% in 0.1% of TFA) at a constant ﬂow rate of 2.5 mL/
min for 90 min. Buffer A was used in the ﬁrst 15 min of the
HPLC run to remove the salts and other reagents. The amino
acid sequence of the peptide was determined using an
Applied Biosystems model Procise f gas–liquid protein
sequencer. The phenylthiohydantoin (PTH) derivatives of
the amino acidswere identiﬁedwith an Applied Biosystems
model 450 microgradient PTH-analyzer.
2.4. Mass spectrometry
The molecular mass of the T. serrulatus natriuretic
peptide (TsNP) was determined using matrix-assisted laser
desorption ionization-time-of-ﬂight (MALDI-TOF) mass
spectrometry on a Voyager-DE PRO MALDI-TOF mass
spectrometer (Applied Biosystems, Life Technologies,
USA). One microliter of the TsNP dissolved in 0.1% TFA was
mixed with 2 mL of the matrix a-cyano-4-hydroxycinnamic
Table 1
Primer sequences used in real time RT-PCR gene expression analyses.
Gene Primer forward (50–30) Primer reverse (50–30) NCBI reference
GC-A GAACCGAAGCTTCCAAGGTG GTGGATATCCCAGAGGCCAGT NM_012613.1
GC-B CATCTGCATCGTCACCGAGT TCCACCACGCAGTTAGAGGAC NM_053838.1
GC-C GGCGGGATACAATCCAGAGAG ACGGTGCCGTAGAACTTGGTC NM_013170.1
NPR-C CCTACAATTTCGACGAGACCAAA TCGCTCACTGCCCTGGAT NM_012868.1
MAPK-1 TGGTTCTACCGGCGGTTAGT AACGAGGAGGGAGGACAACAC NM_053842.1
TGF-b1 GGGCTACCATGCCAACTTCTG GAGGGCAAGGACCTTGCTGTA NM_021578.2
eNOS CGACATTGAGATCAAAGGACTG ACTTGTCCAAACACTCCACGC NM_021838.2
18S rRNA ACATCCAAGGAAGGCAGCAG GCTGGAATTACCGCGGCTG NR_046237.1
Fig. 1. (a) Chromatogram of the fractionation of Tityus serrulatus whole
venom using a Superdex Gel Filtration Column Peptide HR10/300 GL. The
chromatography was monitored simultaneously at 280 nm and 214 nm.
Only fractions VIII and IX were used for further application onto reverse
phase HPLC. (b) Shows the chromatogram of the puriﬁcation of the natri-
uretic peptide from Tityus serrulatus venom (TsNP).
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prepared with 30% acetonitrile and 0.1% TFA (v/v). The
equipment conditions were as follows: accelerating voltage
of 25 kV, laser ﬁxed at 2890 mJ/com2, a delay of 300 ns, and
using a linear analysis mode.
2.5. Homology modeling and alignment
Homology modeling of TsNP was conducted using
MODELLER 9v5 (Sali and Blundell, 1993), with a standard
internal setup and no additional geometrical restraints. A
template search was performed through the PDB database,
using the BLAST algorithm (Altschul et al., 1990) for the
TsNP sequence, with the structure of lebetin 2 isoform
alpha fromMacrovipera lebetina (PDB code: 1Q01) selected.
The following alignment properties with TsNP were found:
E-value: 0.0181276; Score: 35.039 bits (79); Identities: 14/
19 (74%); Positives: 17/19 (89%); Gaps: 0/19 (0%). The PDB
1Q01 structure was used as the template for the homology
modeling. Multiple sequence alignments among the target
(TsNP) and reference sequences were performed using the
ClustalX program (Thompson et al., 1997) with its default
parameters.
2.6. Animals
Adult male Wistar rats (weighing 260–320 g) from the
Animal Facility of Universidade Federal do Ceará were used
in the renal function experiments. The rats were kept in a
housing room with controlled ambient humidity, room
temperature maintained at 22  2 C, laminar air ﬂux and
12 h light/dark circles. All animal studies were performed
according to Brazilian laws for animal experimentation and
were approved by the Ethical Committee of Animal
Experimentation of Universidade Federal do Ceará under
the number 107/07.
2.7. Isolated perfused kidney
The rats (n ¼ 6) were fasted for 24 h with free access to
water before the experiment. The rats were anesthetized
with sodium pentobarbital (50 mg/kg, i.p.). After careful
dissection of the right kidney, the right renal artery was
cannulated via the mesenteric artery without interruption
of blood ﬂow, as described by Bowman (1970) andmodiﬁed
by Fonteles et al. (1983). A modiﬁed Krebs-Henseleit solu-
tion (MKHS, composition inmmol/L: 118.0 NaCl,1.2 KCl,1.18
KH2PO4,1.18MgSO4.7H2O, 2.50 CaCl2 and 25.0NaHCO3)was
used for the perfusion. Bovine serumalbumin (BSA) fractionV (6 g) was added to 100mL of MKHS, and this solutionwas
dialyzed for 48 h at 4 C against 10 volumes of MKHS.
Immediately before the beginning of each perfusion proto-
col, 100 mg of urea, 50 mg of inulin and 50 mg of glucose
were added to the dialyzed solution (100 mL), and the pH
was adjusted to 7.4. In each experiment 100 mL of MKHS
were recirculated for 120 min. The perfusion pressure (PP)
was measured at the tip of the stainless steel cannula in the
renal artery. Samples of urine and perfusate were collected
at 10min intervals for thedeterminationof sodium, chloride
and potassium levels using ion-selective electrodes (Elec-
trolyte Analyzer 9180, Roche). Inulin levels were deter-
mined as described by Walser et al. (1955). Osmolality was
measured with a vapor pressure osmometer (VAPRO
5520,Wescor). TsNP (0.1 mg/mL or 0.03 mg/mL) was added
to the system 30 min after the beginning of each perfusion.
The perfusion pressure (PP), renal vascular resistance (RVR),
urinary ﬂow (UF), glomerular ﬁltration rate (GFR), and the
percentage of sodium (% TNaþ), potassium (% TKþ) and
chloride (% TCl) tubular transport were determined
(Martinez-Maldonato and Opava-Stitzer, 1978). cGMP con-
centrations in the urine samplesweremeasured in triplicate
Fig. 2. Homology modeling between TsNP and the template structure of the
lebentin peptide (PBD code 1Q01). The disulﬁde bonds between cysteine
residues are detailed.
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Aldrich, USA) according to the manufacturer’s instructions.
2.8. Gene expression
Following the protocol of the RNeasyMini Kit (Qiagen–
Valencia, CA, USA), total RNA was extracted from the kid-
neys of four rats per group (Rattus norvegicus); these ani-
mals had been perfused with two different concentrations
of TsNP, as described in Section 2.7. The yield and quality of
total mRNAwere determined spectrophotometrically using
a wavelength of 260 nm and the 260/280 nm wavelength
ratio, respectively. One microgram of RNA, diluted to a ﬁnal
volume of 20 mL, was reverse transcribed into cDNA using
the SuperScript III cDNA Synthesis Kit (Invitrogen Life
Technologies – Carlsbad, CA, USA) with a 96-well MyCycler
thermal cycler (BioRad, Hercules, CA, USA).Fig. 3. (a) Multiple sequence alignment between TsNP and reference sequences (sWe investigated the relative expression of rat kidney
guanylate cyclase receptors-A, -B, -C (GC-A, GC-B, and GC-
C), natriuretic peptide receptor C (NPR-C), endothelial ni-
tric oxide synthase (eNOS), mitogen-activated protein
kinase-1 (MAPK-1), and transforming growth factor beta 1
(TGF-b1); 18S ribosomal RNA (18S rRNA) was used as the
housekeeping gene. Real Time PCR analysis was performed
using the iQ5 Multicolor Real Time PCR Detection System
(Bio-Rad) and the iQ SYBR green Supermix. The speciﬁc
primer sequences (50–30) are shown in Table 1. Thermal
cycling for all genes had an initial denaturation step at
95 C for 3 min followed by 30 cycles for 18S rRNA and 40
cycles for all the other genes. The temperature cycles were
as follows: a denaturing step at 95 C for 30 s for all the
genes; an annealing step at 59 C for GC-A, GC-B, 18S rRNA
and NPR-C; an annealing step at 60 C for eNOS, MAPK-1,
TGF-b1; and an annealing step at 63 C for GC-C also for
30 s. For all the genes underwent, an extension step at
72 C for 45 s. The ﬁnal extension step, was heat the
samples at 72 C for 3 min. After each reaction, we also
performed a melting curve analysis to evaluate the spec-
iﬁcity of the PCR ampliﬁcation. Each PCR reaction well
contained a ﬁnal volume of 25 mL and included 2 mL of
cDNA and gene speciﬁc primers at 200 nM. Negative
samples were run with autoclaved Milli-Q water as the
template. The threshold cycle (CT), deﬁned as the frac-
tional PCR cycle number at which the ﬂuorescence reaches
10 times the baseline standard deviation, was used to
compare the expression of all of the tested genes. The
mathematical method described by Pfafﬂ (2001) was
performed to evaluate the relative expression based on
SYBR green staining.
2.9. Statistical analysis
The data are presented as the mean  SEM. The means
were evaluated by the Student’s t-test or ANOVA followed
by the Bonferroni test, when appropriate. Values of p< 0.05ee details in the text). (b) Neighbor-joining bootstrap tree (1000 replicates).
Fig. 4. Effect of TsNP on a perfused rat kidney evaluating the perfusion
pressure (PP), urinary ﬂow (UF) and glomerular ﬁltration rate (GFR). The
kidneys were perfused with 0.03 and 0.1 mg/mL solution of TsNP and were
compared to those perfused with no substances. Data are expressed as the
mean  SEM and analyzed by ANOVA and the Bonferroni post test.
*p < 0.05.
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5.0 was used for all the statistical analyses.
3. Results
The fractionation of T. serrulatus venom showed the
presence of seven major fractions when the chromatog-
raphy was monitored at 280 nm; nine fractions were
observed at 214 nm. The two last eluted fractions (VIII and
IX) represented the lower molecular mass fractions. Frac-
tion IX had virtually no absorption at 280 nm (Fig. 1a).
Tricine SDS-PAGE analysis of fraction IX showed the pres-
ence of peptides with a molecular mass estimated to be
lower than 3 kDa. Subsequently, fraction IX was lyophilized
and a new fractionationwas performed using reverse phase
HPLC. Among the amino acid sequences of the peptides
found in fraction IX, only one matched with the features of
the natriuretic peptide. This peptide was designated as
TsNP (T. serrulatus Natriuretic Peptide) (Fig. 1b). The mo-
lecular mass of TsNP was determined to be 2190.64 Da (as
shown in Supplementary data). An isoelectric point of
approximately 9.0 was calculated based on the N-terminal
sequencing. The primary structure consisted of 21 amino
acids, “KLSGCFGFKLDRIGTMSGLGC”, and included the
cysteine residues that allowed the formation of a 17 amino
acid ring held by a disulﬁde bridge.
The results obtained by homology modeling of TsNP
using the 1Q01 PDB structure are shown in Fig. 2. The
quality of the model has been veriﬁed using PROCHECK
(Laskowski et al., 1993). The overall G-factor is 0.22 and
there are no residues in the disallowed regions of the
Ramachandran plot.
Multiple sequence alignments among the target (TsNP
peptide) and reference sequences were performedwith the
ClustalX program (Thompson et al., 1997) using the default
parameters. The results can be found in Fig. 3. The reference
structures chosen for this alignment, with their respective
accession numbers, follow: 1) ANPHs (human ANP –
P01160) “SLRRSSCFGGRMDRIGAQSGLGCNSFRY”; 2) BNPHs
(human BNP – P16860) “SPKMVQGSGCFGRKMDRISSSSGL
GCKVLRRH”; 3) CNPHs (human – P23582) “GLSKGCFGL
KLDRIGSMSGLGC”; 4) ANPRn (rat ANP – P01161) “SLRRSSC
FGGRIDRIGAQSGLGCNSFRY”; 5) BNPRn (rat BNP – P13205)
“SQDSAFRIQERLRNSKMAHSSSCFGQKIDRIGAVSRLGCDGLR
LF”; 6) CNPRn (rat CNP–P55207) “GLSKGCFGLKLDRIGSMSG
LGC”; and 7) DNPDa (Dendroaspis DNP – P28374)
“EVKYDPCFGHKIDRINHVSNLGCPSLRDPRPNAPSTSA”.
In isolated perfused rat kidney assay, both concentra-
tions of TsNP (0.03 and 0.1 mg/mL) increased the perfusion
pressure and urinary ﬂowafter 90 and 120min of exposure.
The glomerular ﬁltration ratewas augmented after 120min
at both concentrations. The higher TsNP concentration
(0.1 mg/mL) also increased the GFR after 90 min. These re-
sults are shown in Fig. 4a–c. Renal vascular resistance was
elevated only at 120 min in the group treated with TsNP at
0.1 mg/mL (RVR 1200 Cont. 5.38 0.53; TsNP0.03 5.82 0.48;
TsNP0.1 6.71  0.52* mmHg/mL g1 min1). The percent-
ages of renal transport for sodium, potassium and chloride
were decreased, as was the percentage of sodium proximal
tubular transport, after treatment with TsNP 0.1 mg/mL
(Table 2). Urinary cGMP concentrationwas elevated at bothTsNP concentrations at 60 min (Cont. 8.83  0.70; TsNP0.03
29.50  5.67*; TsNP0.1 41.18  3.25* pmol/mL) but, only for
the higher concentration at 90 min (Cont. 10.81  0.54;
TsNP0.1 46.67  1.60* pmol/mL) and 120 min (Cont.
9.84  1.39; TsNP0.1 68.00  7.60* pmol/mL).
mRNA expression of the natriuretic peptide receptor-A,
-B, -C, and of the guanylate cyclase-C genes was analyzed in
the perfused kidneys because cGMP concentrations were
elevated in the urine samples. NPR-AmRNA expressionwas
down regulated in the kidneys treated with both concen-
trations of TsNP (0.03 and 0.1 mg/mL). In contrast, the NPR-
B, NPR-C and CG-C genes showed an up regulation
following 0.1 mg/mL treatment (Fig. 5). As the expression of
all of the genes was affected and because the NPR-C re-
ceptor does not act via cGMP as a second messenger, we
decided to analyze other genes involved in NPR-C signal
Table 2
Electrolyte transport percentages (%T), in kidneys perfused with 0.03 and 0.1 mg/mL TsNP, were compared to those perfused with no substances. Data are
expressed as the mean  SEM and analyzed by ANOVA and the Bonferroni post test. *p < 0.05. % pT ¼ proximal tubular transport percentage.
Time (min)
30 60 90 120
% TNaþ
Control 81.94  1.24 81.11  1.52 79.26  0.90 79.76  0.56
TsNP 0.03 mg/mL 79.52  1.76 77.50  1.86 76.59  2.68 68.34  4.37
TsNP 0.1 mg/mL 80.77  1.42 70.88  2.22* 70.72  2.04* 64.84  2.90*
% TKþ
Control 69.13  4.14 69.04  5.68 71.84  4.21 69.94  6.86
TsNP 0.03 mg/mL 69.16  3.68 65.41  4.39 67.32  4.90 65.54  3.91
TsNP 0.1 mg/mL 70.04  3.27 49.68  7.24* 47.60  9.37* 50.81  6.46*
% TCl
Control 79.90  1.03 81.25  2.44 77.32  2.22 78.53  2.33
TsNP 0.03 mg/mL 78.42  1.78 75.95  2.51 76.77  1.24 71.50  1.23*
TsNP 0.1 mg/mL 81.90  3.68 76.15  3.42 72.89  3.86 69.02  3.64*
% pTNaþ
Control 77.69  1.68 75.59  0.90 77.33  1.33 78.18  1.97
TsNP 0.03 mg/mL 76.77  1.07 73.36  2.82 75.04  1.93 69.02  2.84*
TsNP 0.1 mg/mL 80.64  1.18 71.49  5.02 70.36  0.98* 59.50  1.75*
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eNOS, MAPK-1 and TGFb-1. A down regulation of eNOS
mRNAwas observed for both TsNP concentrations (Control
1.046  0.082; TsNP0.03 0.156  0.046*; TsNP0.1
0.276  0.083* relative expression rate). However, an up
regulation of TGFb-1 mRNA was found for 0.1 mg/mL TsNP
concentration (Control 1.124  0.345; TsNP0.03
2.751  0.969*; TsNP0.1 4.459  1.020* relative expression
rate). MAPK-1 gene expressionwas not affected by the TsNP
treatment.Fig. 5. Relative mRNA expression of natriuretic peptide receptors-A, -B and -C (NPR-
0.03 and 0.1 mg/mL of TsNP and those of control group. The expression of 18S r
mean  SEM for 6 animals. *p < 0,05 compared to control group using ANOVA an4. Discussion
Natriuretic peptides have been extensively investigated
due to their potential for the treatment of cardiovascular
diseases such as congestive heart failure. Despite all the
advances that have been made in this ﬁeld, only two NP-
based drugs have been produced. Unfortunately, both of
these drugs possess poor pharmacokinetic properties and
have adverse effects that limit their use (Vink et al., 2010).
Since the discovery of venom-related natriuretic peptides,A, NPR-B and NPR-C) and guanylate cyclase C (GC-C) in kidneys perfused with
ibosomal RNA was used as a housekeeping gene. Data are reported as the
d the Bonferroni post test.
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peptides have been produced. These have resulted in pep-
tides with greater stabilities and new pharmacological
properties. These peptides have shown advantages over
their mammalian counterparts for therapeutic use (Lisy
et al., 2008; Vink et al., 2010).
In platypus and snake venoms, natriuretic peptides are
encoded in the same gene regions of bradykinin-
potentiating peptides (BPP) or metalloprotease-inhibiting
peptides and are posttranslationally liberated (Fry et al.,
2009). This is the ﬁrst report of the isolation of a natri-
uretic peptide from scorpion venom. Sequence alignment
of TsNP shows a structural similarity to C-type natriuretic
peptides. Recently, a family of peptides was isolated from T.
serrulatus venom. These peptides shared a sequence
signature with the bradykinin-potentiating peptides (BPP)
found in snake venom (Verano-Braga et al., 2008). Higuchi
et al. (1999) showed that BPP and C-type natriuretic pep-
tide are encoded by the same genes in species of the Cro-
talinae subfamily. Herein a question arises: are TsNP and
the hypotensins also encoded by the same gene sequence?
Sequence alignment of TsNP with human and rat ANP,
BNP and CNP (Fig. 3) showed a higher homology of TsNP for
both, human and rat CNP. Based on this result, a higher
afﬁnity of TsNP for NPR-B and NPR-C is expected. NPR-B has
approximately a 50-fold higher afﬁnity for CNP than ANP.
CNP essentially does not bind to NPR-A but, it binds to NPR-
B and NPR-C with similar afﬁnities (Schulz, 2005).
The effects of TsNP on the isolated perfused rat kidney
were similar to those reported by Evangelista et al. (2008)
for a natriuretic peptide from C. durissus cascavella
venom. In the same perfusion system, ANP also showed an
increase in GFR and urine ﬂow, with no effect in the
perfusion pressure. The urinary excretion of sodium, po-
tassium and chloride were increased by the TsNP treat-
ment, as has been shown for ANP, guanylin and urodilatin
(Santos-Neto et al., 2006). The concentration of cGMP in the
urine was elevated as would be expected for a guanylate
cyclase activating drug. CD-NP, a chimeric natriuretic pep-
tide, has been shown to enhance GFR, producing diuresis
and natriuresis (Lisy et al., 2008).
Fonteles et al. (2009) showed a reduction in NPR-A
expression accompanied by an increase in GC-C expres-
sion in animals receiving a high-salt diet and treated with
uroguanylin (a GC-C agonist). This observation corrobo-
rates with our data, which showed that GC-C expression
was elevated while NPR-A expression was down regulated
following treatment with TsNP. These effects point to a
possible activation of GC-C by TsNP. However, Anand-
Srivastava (2005) demonstrated another possible relation-
ship, which could explain NPR-A down regulation and link
the up regulation of TGFb-1 and NPR-C, with the down
regulation of NPR-A. These results were also observed in
our studies.
The increased concentration of cGMP in the urine points
to the activation of guanylate cyclase, as occurs after NPR-B
and GC-C activation. NPR-C could play a role in the
increased perfusion pressure caused by TsNP. NPR-C has
three distinct signaling pathways, which involve the acti-
vation of eNOS, MAPK-1 and phospholipase C (PLC)
(Anand-Srivastava, 2005). For this reason, the geneexpression of eNOS and MAPK-1 following TsNP treatment
were also tested. TsNP treatment resulted in down regu-
lation of eNOS expression, whereas MAPK-1 expression
was not changed. This result possibly excludes the
involvement of these two NPR-C signaling pathways in the
biological actions of TsNP. Thus, activation of PLC down-
stream might explain the augmentation of the perfusion
pressure through direct vascular smooth muscle contrac-
tion (Anand-Srivastava, 2005).
In conclusion, this work describes the isolation and
modeling of the ﬁrst natriuretic peptide isolated from
scorpion venom. In addition, the renal actions and the ef-
fects on NPRs mRNA expression in the kidneys are delin-
eated. Our data showed that TsNP might act promiscuously
with NPR-B, NPR-C and GC-C. Future binding analyses
should elucidate the relative afﬁnities between TsNP and
various receptors.
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